MGX
$1.46
Metagenomi Therapeutics, Inc.
Recent News
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Metagenomi Therapeutics: Q4 Earnings Snapshot
EMERYVILLE, Calif. AP) — Metagenomi Therapeutics, Inc. MGX) on Thursday reported a loss of $22.5 million in its fourth quarter.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -24.49% and -5.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Amazon Launches New AI Chip While Teasing Future Tech Collaboration With Nvidia
Amazon stock was higher after the tech giant announced its Trainium3 AI chip is now available for customers of AWS.